I
22.77
0.75 (3.41%)
| Previous Close | 22.02 |
| Open | 22.28 |
| Volume | 198,554 |
| Avg. Volume (3M) | 1,739,023 |
| Market Cap | 3,991,046,656 |
| Price / Book | 7.70 |
| 52 Weeks Range | |
| Earnings Date | 5 Feb 2026 |
| Diluted EPS (TTM) | -2.73 |
| Total Debt/Equity (MRQ) | 0.01% |
| Current Ratio (MRQ) | 11.16 |
| Operating Cash Flow (TTM) | -375.87 M |
| Levered Free Cash Flow (TTM) | -227.82 M |
| Return on Assets (TTM) | -37.97% |
| Return on Equity (TTM) | -62.46% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Immunovant, Inc. | Bearish | Bearish |
AIStockmoo Score
-1.5
| Analyst Consensus | -0.5 |
| Insider Activity | -3.0 |
| Price Volatility | -4.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.5 |
| Average | -1.50 |
|
Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 58.17% |
| % Held by Institutions | 55.78% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 33.00 (JP Morgan, 44.93%) | Buy |
| Median | 24.50 (7.60%) | |
| Low | 16.00 (Truist Securities, -29.73%) | Hold |
| Average | 24.50 (7.60%) | |
| Total | 1 Buy, 1 Hold | |
| Avg. Price @ Call | 16.81 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Truist Securities | 14 Oct 2025 | 16.00 (-29.73%) | Hold | 17.49 |
| JP Morgan | 30 Sep 2025 | 33.00 (44.93%) | Buy | 16.12 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| FROMKIN ANDREW J. | - | 22.75 | -22,249 | -506,165 |
| HUGHES DOUGLAS J. | - | 22.75 | -15,000 | -341,250 |
| Aggregate Net Quantity | -37,249 | |||
| Aggregate Net Value ($) | -847,415 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 22.75 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| HUGHES DOUGLAS J. | Director | 01 Dec 2025 | Automatic sell (-) | 15,000 | 22.75 | 341,250 |
| FROMKIN ANDREW J. | Director | 01 Dec 2025 | Automatic sell (-) | 22,249 | 22.75 | 506,165 |
| Date | Type | Details |
|---|---|---|
| 10 Nov 2025 | Announcement | Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025 |
| 27 Oct 2025 | Announcement | Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |